8 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Imaging Innate Immunity of Staphylococcal Infections (PSMS-IN-INFLAMMATION)
Date du début: 9 avr. 2014, Date de fin: 8 avr. 2017,
"Staphylococcus aureus community-acquired (CA)-MRSA strains are highly virulent and can cause infections in otherwise healthy individuals and are a leading cause of death worldwide. Innate immunity is our primary defense against invading staphylococci. Blood-neutrophils migrate to the site of infection where they, in concert with the complement system, engulf and kill bacteria in a process called ...
Voir le projet
1
Participant partenaire
TERMINÉ
Determinants of the switch from R5- to X4-tropic virus in HIV-1 infected individuals (SwitchR5-X4)
Date du début: 1 oct. 2013, Date de fin: 15 déc. 2016,
HIV-1 variants utilizing CCR5 (R5) are predominant during early infection, emergence of CXCR4 (X4) strains typically occurs later. Although R5 to X4 switch is strongly correlated with increased rates of disease progression, it remains largely unknown which factors are causing the switch. Based on our preliminary data we postulate that both host (immune activation) and viral factors (target cell af ...
Voir le projet
1
Participant partenaire
TERMINÉ
Microvesicle-inspired drug delivery systems (MINDS)
Date du début: 1 déc. 2010, Date de fin: 30 nov. 2015,
Current state-of-the-art drug carrier systems deliver new ‘biological drugs’ (like proteins and nucleic acids) poorly to the target site. This is something I daily experience in my research on delivery of small interfering RNA. The in vivo challenges are threefold:• Biological drugs are fragile molecules (subject to degradation and denaturation)• They need to gain access to the target site• They n ...
Voir le projet
2
Participants partenaires
TERMINÉ
ATMP GMP Open Access Research Alliance - AGORA (AGORA)
Date du début: 1 sept. 2013, Date de fin: 31 oct. 2015,
We propose an academic & industrial partnership to facilitate safe and effective delivery of new advanced therapy medicines within the framework of the relevant EU regulations which our previous FP7 funded project have identified as creating unanticipated barriers to development of this field. Over 80% of advanced therapy medicines (ATMPs) trials in the EU are academic investigator led and sponsor ...
Voir le projet
8
Participants partenaires
TERMINÉ
Evolution and Transfer of Antibiotic Resistance (EVOTAR)
Date du début: 1 oct. 2011, Date de fin: 30 sept. 2015,
Antibiotics are essential therapeutics in the treatment of bacterial infections. However, the indiscriminate use of antibiotics has led to the emergence of antibiotic resistant bacteria that pose a major threat to human health as options for treating infections by these bacteria have become limited. The evolution, emergence and spread ofantibiotic resistance genes are still only poorly understood ...
Voir le projet
19
Participants partenaires
TERMINÉ
Collaborative HIV and Anti-HIV Drug Resistance Network (CHAIN)
Date du début: 1 avr. 2009, Date de fin: 31 mars 2014,
CHAIN is a large scale integrating project aimed to effectively and durably combat new and existing anti-HIV drug resistance in clinical settings, with a special emphasis on Eastern Europe and in heavily affected resource-poor regions in Africa. This will be achieved through our pan-European network of surveillance and basic research activities, the involvement of all main actors in the field of H ...
Voir le projet
28
Participants partenaires
TERMINÉ
TARGET MV: Proof of concept study to commercialise a microvesicle-based drug delivery system (TARGETMV)
Date du début: 1 mai 2012, Date de fin: 30 avr. 2013,
"Biological drugs such as proteins and nucleic acids have poor bioavailability, are subject to degradation and denaturation and need to be delivered to a specific cell type and sometimes even a specific organelle to be active. Therefore, they require a drug delivery system to bring them to the target site. However, the current available drug delivery systems lack efficiency, resulting in poor effi ...
Voir le projet
1
Participant partenaire
TERMINÉ
CONtrol of COmmunity-acquired MRSA: Rationale and Development of counteractions (CONCORD)
Date du début: 1 janv. 2009, Date de fin: 30 juin 2012,
"Until recently, methicillin-resistant Staphylococcus aureus (MRSA) were confined to hospitals (HA-MRSA). However, community- and farm-associated MRSA (CA-and FA-MRSA) has developed as an important cause of infections. No strategies exist to combat these MRSA. CONCORD is aimed at explaining the ecological success in the community and the farm environment of CA- and FA-MRSA in contrast to HA-MRSA i ...
Voir le projet